Standard BioTools Inc. Operating Lease Right-of-Use Assets
Standard BioTools Inc. (LAB) had Operating Lease Right-of-Use Assets of $24.25 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Operating Lease, Right-of-Use Asset $24.25M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $25.55M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $26.73M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $23.45M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $24.25M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $25.55M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $26.73M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $23.45M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $24.57M 10-Q · filed 2025-08-15 | |
| 2025-03-31 | $27.42M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $26.57M 10-K · filed 2026-03-16 | $28.83M 10-K · filed 2025-03-11 |
| 2024-09-30 | $30.26M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $31.53M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $32.97M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $30.66M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $31.19M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $32.19M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $32.97M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $33.88M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $34.73M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $35.41M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $36.39M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $37.12M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $37.70M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $38.72M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $37.24M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $38.11M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $38.47M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $39.03M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $39.50M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $4.86M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $5.35M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $6.51M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $7.18M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |